Evidence map›Paper›PMID 29497113›Full record

ArticleScientific reports2018

Tolerance of chronic HDACi treatment for neurological, visceral and lung Niemann-Pick Type C disease in mice.

Md Suhail Alam, Bruce Cooper, Joseph D Farris, Kasturi Haldar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Inherited disorders of lysosomal membrane transporters.Biochimica et biophysica acta. Biomembranes · 2020
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Md Suhail AlamBoler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA.
Bruce CooperBindley Bioscience Center, Discovery Park, Purdue University, West Lafayette, IN, 47907, USA.
Joseph D FarrisBoler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA.
Kasturi HaldarBoler-Parseghian Center for Rare and Neglected Diseases, University of Notre Dame, Notre Dame, IN, 46556, USA. khaldar@nd.edu.ORCID 0000-0001-5065-158X
University of Notre Dame · USPurdue University West Lafayette · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histone deacetylase (HDAC) inhibitors are of significant interest as drugs. However, their use to treat neurological disorders has raised concern because HDACs are required for brain function. We have previously shown that a triple combination formulation (TCF) of the pan HDACi vorinostat (Vo), 2-hydroxypropyl-beta-cyclodextrin (HPBCD) and polyethylene glycol (PEG) 400 improves pharmacokinetic exposure and entry of Vo into the brain. TCF treatment significantly delayed both neurodegeneration and death in the Npc1

Indexed as

2-Hydroxypropyl-beta-cyclodextrinAnimalsBrainDisease Models, AnimalDisease ProgressionDrug CombinationsDrug ToleranceFemaleHistone Deacetylase InhibitorsHistone DeacetylasesImmune ToleranceIntracellular Signaling Peptides and ProteinsLungLung DiseasesMaleMice2-Hydroxypropyl-beta-cyclodextrinDrug CombinationsHistone Deacetylase InhibitorsHistone DeacetylasesIntracellular Signaling Peptides and ProteinsNiemann-Pick C1 ProteinNpc1 protein, mousepolyethylene glycol 400Polyethylene GlycolsProteinsVorinostat

Identifiers

PMID29497113
PMCPMC5832807
OpenAlexW2806583136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.